A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Recruiting · NCT06868199 · Registry updated 2025-09-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours | Advanced Solid Tumours | Recruiting | Phase 1 / Phase 2 | 2025-09-12 | NCT06868199 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| LaNova Medicines Limited | 13 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Bayview Health-Investigational Drug Services | Perth | Australia | 1 |
| Beijing Cancer Hospital | Beijing | China | 55 |
| Cancer Care Wollongong Pty Limited | Wollongong | Australia | 3 |
| Macquarie University | Ryde | Australia | 1 |
| MUPharm Pty Limited trading as Macquarie University Hospital Parmarcy | Ryde | Australia | 1 |
| One Clinical Reasearch | Perth | Australia | 1 |